

1 Article

2 PD-1/PD-L1 Blockade Combined with AbnobaViscum® Thera- 3 py is Linked to Improved Survival in Advanced or 4 Metastatic NSCLC Patients, an ESMO-GROW Related Re- 5 al-World Data Registry Study

6 Friedemann Schad ^{1,2,*§}, Anja Thronicke ^{1,*§}, Ralf-Dieter Hofheinz ³, Reinhild Klein ⁴, Patricia Grabowski ^{2,5},
7 Shiao-Li Oei ¹, Hannah Wüstefeld ⁶ and Christian Grah ⁶

8 ¹ Research Institute Havelhöhe, Network Oncology Registry, Kladower Damm 221, 14089 Berlin, Germany,
9 FSchad@havelhoehe.de; Anja.Thronicke@havelhoehe.de, ShiaoLi.Oei@havelhoehe.de

10 ² Hospital Havelhöhe, Interdisciplinary Oncological Centre, Kladower Damm 221, 14089 Berlin, Germany,
11 FSchad@havelhoehe.de, Patricia.Grabowski@havelhoehe.de

12 ³ Mannheim University Hospital, Mannheim Cancer Center, Theodor-Kutzer Ufer 1-3, 68167 Mannheim,
13 Germany, Ralf-Dieter.Hofheinz@medma.uni-heidelberg.de

14 ⁴ University Hospital Tübingen, Department of Internal Medicine II, Otfried-Müller Straße 10, 72076
15 Tübingen, Germany, reinhild.klein@med.uni-tuebingen.de

16 ⁵ Charité – Universitätsmedizin Berlin, Charité Fatigue Centrum, Augustenburger Platz 1, 13353 Berlin
17 Germany, Patricia.Grabowski@charite.de

18 ⁶ Hospital Havelhöhe, Lung Cancer Center, Kladower Damm 221, 14089 Berlin, Germany,
19 Christian.Grah@havelhoehe.de; Hannah.Wuestefeld@havelhoehe.de

20 * Correspondence: fschad@havelhoehe.de, +49 30 36501 7019; anja.thronicke@havelhoehe.de; +49 30 36501 5015

21 § both authors contributed equally to this work.

22 **Abstract: Background:** Recent advancements in cancer treatment have shown the potential of
23 PD-1/PD-L1 inhibitor (ICB) plus *Viscum album* L. (VA) therapy in improving survival rates for pa-
24 tients with advanced or metastasized non-small cell lung cancer (NSCLC). The objective of this
25 study was to investigate factors associated with improved survival in NSCLC patients treated with
26 a combination of ICB and VA. **Methods:** Patients with advanced or metastasized NSCLC from the
27 accredited national Network Oncology registry were included in the real-world data study adher-
28 ing to ESMO-GROW criteria. The study was conducted with ethics approval. Survival and the
29 impact on hazard were compared between patients receiving PD-1/PD-L1 inhibitor therapy alone
30 versus combinational PD-1/PD-L1 inhibitors and abnobaViscum® therapy. Adjusted multivariate
31 Cox proportional hazard analysis was utilized to examine factors linked to survival. **Results:** En-
32 rolled patients (n = 300) had stage III or stage IV NSCLC, had a 1.19 male/female ratio and were 68
33 years old (median). Two hundred and twenty-two patients (74%) were in the control (CTRL,
34 PD-1/PD-L1 inhibitor therapy) and seventy-eight patients (26%) in the combinational (COMB,
35 PD-1/PD-L1 inhibitor plus abnobaViscum® therapy) group. The three-year survival was signifi-
36 cantly prolonged by 7 months when abnobaViscum® therapy was added to the anti-PD-1/PD-L1
37 therapy (Comb: 13.8 months vs. Control: 6.8 months, p = 0.005). The three-year survival rate was
38 16.5% in the COMB group and two times higher than the three-year survival rate in the CTRL
39 group (8.0%). Adjusted multivariable Cox regression analysis was performed for patients with
40 PD-L1 positive (≥1%) NSCLC treated with a first-line PD-1 inhibitor and revealed that the addition
41 of abnobaViscum® therapy to anti-PD-1 significantly lowered the hazard of death by 75% in (aHR:
42 0.25; 95%CI: 0.11-0.60, p=0.002). **Conclusions:** Our results indicate that addition of abnobaViscum®
43 therapy is significantly linked to enhanced survival in patients with advanced or metastasized
44 NSCLC who are undergoing treatment with standard PD-1/PD-L1 inhibitor therapy irrespective of
45 their age, tumor stage, ECOG status, surgery or radiation. The mechanisms could involve a syner-
46 gistic modulation of the immune response, reduced primary PD-1/PD-L1 inhibitor resistance via
47 immunogenic cell death and/or modification of the tumor microenvironment by combinational
48 PD-1/PD-L1 inhibitor and abnobaViscum® therapy. Our findings should be complemented with

49 analyses of RCT or R-RCT.
50 Trial registration: The study was registered retrospectively (DRKS00013335).

51 **Keywords:** PD-1 inhibitor; PD-L1 inhibitor; survival; abnobaViscum® therapy; non-small cell lung
52 cancer; lung cancer

53 1. Introduction

54 Lung cancer is the leading cause of cancer-related deaths and only one in ten pa-
55 tients with metastatic non-small cell lung cancer (NSCLC) survives 5 years or more.
56 However, the advancements in immune checkpoint blockade (ICB) targeting PD-1 (pro-
57 grammed cell death protein 1) or PD-L1 (programmed death-ligand 1) receptors im-
58 proved survival rates of patients with metastatic NSCLC (1). Combinations, timing and
59 duration of currently approved PD-1 inhibitors (pembrolizumab, nivolumab) or PD-L1
60 inhibitors (durvalumab, atezolizumab) are constantly modified due to rapid advance-
61 ments and developments in clinical trials (2-9). Current improvements involve the
62 first-line application of anti-PD-1/PD-L1 therapy reflecting the race for a cure of such a
63 destructive disease (4, 5, 9).

64 *Viscum album* L. extracts (European white-berry mistletoe, VA) being applied in ad-
65 dition to PD-1/PD-L1 blockade in advanced or metastasized NSCLC patients were shown
66 to be linked to improved overall survival (64). Clinical safety studies have found no
67 safety issues with the use of VA in conjunction with anti-PD-1/PD-L1 therapy (13, 14, 40)
68 and the national guideline for complementary therapies in oncological patients indicates
69 there is no evidence of an increased rate of serious adverse events with the simultaneous
70 use of immune checkpoint inhibitors and VA (46). The aim of this study was to assess the
71 overall survival of patients with advanced or metastatic NSCLC patients undergoing
72 standard-oncological immunotherapy, both with and without abnobaViscum® therapy.
73 To achieve the study objectives, we chose RWD as our primary data source from regis-
74 try-based data. This source was deemed particularly suitable due to its relevance and the
75 ability to provide a comprehensive picture of real clinical practice. In recent years, the use
76 of Real-World Data (RWD) has gained significance, particularly in evidence generation
77 for clinical studies. This methodology facilitates the identification of relevant subgroups,
78 such as elderly NSCLC patients with a performance status of ≥ 1 or those with multiple
79 comorbidities, from real-world clinical settings. This approach generates targeted evi-
80 dence essential for evaluating the effectiveness of ICB, both with and without
81 abnobaViscum® therapy.

82 2. Materials and Methods

83 2.1. Study Design

84 This study is a real-world data (RWD) analysis using information from a German
85 Cancer Society accredited source, the oncological registry Network Oncology (NO) (31)
86 in line with the ESMO – Guidance for Reporting Oncological real-World Evidence
87 GROW criteria, see supplementary material. Enrolment of patients was from July 2015 to
88 May 2023. Patients received abnobaViscum® therapy in line with the summary of product
89 characteristics (SmPC) (32) and at the discretion of the physician. PD-1/PD-L1 inhibitors
90 were administered alone or in combination with VA according to standard clinical prac-
91 tice. The rationale for using VA therapy in patients in this study was to enhance survival,
92 improve health-related quality of life, and alleviate cancer- and treatment-related symp-
93 toms. AbnobaViscum® extracts were given to the patients at the physician's discretion.
94 The primary objective was to evaluate overall survival of patients with advanced or me-
95 tastized NSCLC receiving anti-PD-1/PD-L1 treatment with and without abnobaVis-
96 cum® therapy. The secondary outcome aimed to descriptively assess whether specific
97 variables were linked to a reduced risk of death. The analysis included patients with
98 advanced or metastatic NSCLC (UICC stage III-IV) who had received first-line immune
99 checkpoint inhibitor therapy, with or without abnobaViscum® therapy, and were regis-
100 tered in NO database. Additional inclusion criteria included patients aged 18 years and

101 older, of any gender, who provided written consent. Demographic, diagnosis, tumor
102 stage, treatment and survival as well as tumor board and last contact data were extracted
103 from the NO registry. The use of VA extracts in an integrative oncological setting was
104 documented, including start and end dates, dosages, data of host tree of the VA. Fol-
105 low-up was routinely conducted six months after the initial diagnosis and annually in
106 subsequent years. Loss to follow-up was defined as the absence of any follow-up visits.

107 2.2. *Interdisciplinary Team*

108 The multidisciplinary team of the presented study consisted of experts from various
109 fields, including clinical practice, epidemiology, and biostatistics. This diversity of ex-
110 pertise was crucial in meeting the requirements of a successful RWD study according to
111 the ESMO-GROW criteria. Through close collaboration, we ensured that all aspects of the
112 study were comprehensively addressed.

113 2.3. *Ethics issues*

114 The study adheres to the principles outlined in the Declaration of Helsinki. Written
115 informed consent was obtained from all patients prior to their enrollment. The study was
116 approved by the ethics committee of the Medical Association Berlin (Eth-27/10).

117 2.4. *Classification of Groups*

118 Patients with NSCLC were categorized into histological subgroups non-squamous
119 cell carcinoma, squamous cell carcinoma, or large cell carcinoma. Patients were then as-
120 signed to one of the two groups: 1) the CTRL group, which received only PD-1/PD-L1
121 inhibitors without VA therapy, or 2) the COMB group, which received PD-1/PD-L1 in-
122 hibitors along with additional abnobaViscum® therapy. The allocation to treatment
123 groups was non-randomized and determined by the physician, following detailed in-
124 formation and the patient's decision regarding treatment options. The VA therapy in-
125 cluded abnobaViscum® (ABNOBA GmbH, Niefern-Öschelbronn) extracts and extracts
126 from other producers (Helixor Heilmittel GmbH, Rosenfeld; Iscador AG, Arlesheim).

127 2.5. *Determination of Sample Size*

128 To determine the necessary sample size for a two-sided test with an 80% power and a
129 significance level of 5% using an allocation ratio of 0.2 (CTRL) to 0.8 (COMB) and an ef-
130 fect size of 0.6 (10, 33), a total of 219 patients would be required. This included 44 patients
131 in the COMB and 175 patients in the CTRL group, in order to confirm a statistically sig-
132 nificant treatment effect, as outlined by Schoenfeld et al. (34).

133 2.6. *Statistical Methods*

134 Continuous variables were summarized using the median and interquartile range
135 (IQR), while categorical variables were reported as absolute and relative frequencies.
136 Data distributions were visually inspected, and skewness was evaluated arithmetically.
137 Patients with missing data were excluded from the analysis. Baseline characteristics and
138 treatment regimens for both group were compared using the unpaired Student's t-test for
139 independent samples. Chi-square analysis was used for comparisons of categorical varia-
140 bles. All statistical tests were two-sided, and all analysis were exploratory in nature.
141 Kaplan-Meier survival curves were generated for both groups CTRL and COMB group.
142 Patient survival was calculated from the index date until the last recorded event includ-
143 ing either the date of death, the last documented personal contact, the last interdiscipli-
144 nary tumor board, or follow-up. For survival analyses, the index date was defined as the
145 first date of start of anti-PD-1/PD-L1 therapy. Patients who had not died by the time of the
146 analysis were censored. A year was defined as 365.25 days, and a month at 365.25/12
147 days.


148 To examine the influence of various factors on patient survival while minimizing
149 potential confounding, we employed a multivariate stratified Cox proportional hazards
150 model, adjusting for age, gender, tumor stage, ECOG performance status, PD-L1 status,

151 and oncological treatment. Before conducting this analysis, we performed verification
152 analyses to ensure that the proportional hazard assumptions were satisfied. All analyses
153 were conducted using R-Studio version 2022.02.2 and R software version 4.1.2
154 (2021-11-01) “bird hippie”, which is a language and environment for statistical compu-
155 ting (35). For Kaplan-Meier survival analysis, and multivariate Cox proportional hazards
156 analysis we utilized the R package ‘survival’ (version 3.5-5) (36). The ‘prodlim, package
157 was used for implementing nonparametric estimators for censored event history (sur-
158 vival) analysis (version 2019.11.13) (37). To draw survival curves the package ‘survminer’
159 was used, version 0.4.9 (38). The statistical analyses in this study not only encompass the
160 outcomes but also take into account the internal and external validity of the data. We
161 conducted sensitivity analyses such as subgroup analyses to verify the robustness of our
162 results, to reduce potential biases and to understand variations in the response.

163 3. Results

164 3.1. Baseline Characteristics

165 Three hundred (n = 300) patients with advanced or metastasized NSCLC who re-
166 ceived PD-1/PD-L1 inhibitors as part of their standard of care being documented in the
167 network oncology registry were included in the study. Out of the total, 222 patients (74%)
168 were treated with immune checkpoint inhibitors alone without on the addition of abno-
169 baViscum® therapy (control group, CTRL) while 78 patients (26%) received PD-1/PD-L1
170 inhibition in combination with abnoBaViscum® therapy (combinational group, COMB)
171 (see flowchart, Figure 1). In total, 300 patients were included for the Kaplan-Meier sur-
172 vival analysis and one hundred and twenty one patients were enrolled for the adjusted
173 multivariate cox regression analysis. The latter group had a PD-L1 positive ($\geq 1\%$) NSCLC
174 and were treated with a first-line PD-1/PD-L1 inhibitor therapy only, see figure 1.



175
176 **Figure 1.** Study process flow. Patients with advanced or metastasized NSCLC who received
177 PD-1/PD-L1 inhibitors, either with or without abnoBaViscum® therapy (n=300), CTRL, received
178 PD-1/PD-L1 inhibitors and no abnoBaViscum® therapy; COMB, received PD-1/PD-L1 inhibitors in
179 conjunction with abnoBaViscum® therapy; ICB, immune checkpoint blockade; n, number; abno-
180 baViscum®, abnoBaViscum® therapy; PD-L1 $\geq 1\%$, $\geq 1\%$ tumor proportion score of programmed
181 death-ligand 1.

182 No significant differences were observed between the two groups regarding gender,
183 histology, tumor stage, and surgery. The median age of the total cohort was 68 years (in-
184 terquartile range 62-76). Participants from the COMB group were in median three years
185 younger than participants from the CTRL group, the difference was not significant, see

186 table 1. The sex ratio (male/female) was 1.19. The most common histological subtype of
 187 NSCLC was non-squamous cell carcinoma, accounting for 63% (n=189) of cases, followed
 188 by squamous cell carcinoma with 30% (n=90), as shown in table 1. In 7% of patients
 189 (n=21), the diagnosis of NSCLC was not further specified due to the nature of real-world
 190 data. In the COMB group, the percentage of patients with non-squamous cell carcinoma
 191 was slightly lower at 61.5% compared to 63.5% in the CTRL group, however, the differ-
 192 ences between the groups were not statistically significant.

193 **Table 1.** Characteristics of patients.

	Total cohort (n=415)		CTRL (n=222)		COMB (n=78)		p-value
	N	%	N	%	N	%	
Age at first diagnosis, median years (IQR)	68	(62-76)	69.5	(63.5-76.8)	66.5	(60.3-74.0)	0.686
Gender							0.305
Female	137	45.7	97	43.7	40	51.3	
Male	163	54.3	125	56.3	38	48.7	
Histology							0.302
non-squamous	189	63.0	141	63.5	48	61.5	
squamous	90	30.0	63	28.4	27	34.6	
NSCLC, NA	21	7.0	18	8.1	3	3.8	
ECOG							0.538
0	68	22.7	50	22.5	18	23.1	
1	113	37.7	100	45.0	13	16.7	
2	39	13.0	33	14.9	6	7.7	
3	18	6.0	14	6.3	4	5.1	
4	6	2.0	3	1.4	3	3.8	
5	4	1.3	3	1.4	1	1.3	
UICC stage							0.08
UICC stage III	62	20.7	40	18.0	22	28.2	
UICC stage IV	238	79.3	182	82.0	56	71.8	

194 Patient characteristic, please note that the percentages of sub-variables may not sum to 100% due
 195 to rounding; IQR refers to the interquartile range; CTRL indicates patients treated with
 196 PD-1/PD-L1 inhibitors alone, while COMB refers to patients receiving PD-1/PD-L1 inhibitors in
 197 conjunction with VA therapy. UICC stands for Union International Centre le Cancer staging based
 198 on the UICC TNM classification system; ECOG represents the Eastern Cooperative Oncology
 199 Group.

200 3.2. Tumor Markers

201 No significant differences in molecular marker were noted between the two groups,
 202 except for PD-L1 status, as shown in table 2. In the CTRL-group, there was a 19.3% higher
 203 percentage of patients with a positive PD-L1 status and a 20.1% higher percentage with
 204 PD-L1 ≥ 50 TPS compared to the COMB group, and these differences were statistically
 205 significant. PD-L1 status was available for 82.3% (n=247) of the patients assessed, while
 206 the documentation of known BRAF mutations, EGFR (exon 18-21) mutations, ROS rear-
 207 rangements, and ALK translocations varied from 52.3% to 100%, as detailed in table 2.
 208 Regarding stage IV NSCLC, the molecular status was recorded for 184 (61.3%) of the 238
 209 patients.

210

Table 2. Molecular characteristics of patient's non-small cell lung cancer.

	Total cohort (n=300)		CTRL (n=222)		COMB (n=78)		p-value
	N	%	N	%	N	%	
PD-L1 status							0.007
PD-L1 status, positive/known	171/247	69.2	137/185	74.1	34/62	54.8	
PD-L1 status, positive TPS	85/247	34.9	73	39.5	12	19.4	0.007
≥50/known							
ALK translocation							1
negative/known	170/171	94.4	124/125	99.2	46/46	100	
EGFR (Exon 18-21) mutation							0.070
negative/known	136/148	91.9	106/112	94.6	30/36	83.3	
ROS1-rearrangement							0.596
negative/known	150/300	50.0	108/222	48.6	42/78	53.8	
BRAF V600E-mutation							0.724
negative/known	154/157	98.1	114/117	97.4	40/40	100	

211 Molecular characteristics of patients with NSCLC, CTRL refers to patients receiving PD-1/PD-L1
 212 inhibitors alone, while COMB denotes patients treated with PD-1/PD-L1 inhibitors plus VA. ALK,
 213 anaplastic lymphoma kinase; BRAF, B-rapidly accelerated fibrosarcoma; EGFR, epidermal growth
 214 factor receptor; PD-L1 programmed death ligand 1; ROS1, receptor tyrosine kinase encoded by the
 215 ROS1 gene; TPS, tumor proportion score.

216 *3.3. Oncological Treatment*

217 Almost 60 percent of all enrolled patients received a first-line PD-1/PD-L1 therapy.
 218 PD-1 inhibitors were the most group (92%) compared to PD-L1 inhibitors (7%), see table
 219 3. There was no significant difference in PD-1 or PD-L1 inhibitor treatment between the
 220 two groups. 13.6% more patients from the CTRL group received first-line treatment, a
 221 difference which was close to significance. Eleven percent of enrolled patients received a
 222 radiation of the lung and nine percent a radiation of the brain. Eleven percent of the pa-
 223 tients also received a surgery and four percent a chemotherapy. While 9.3% more patients
 224 of the COMB group received surgery compared to CTRL (p=003) no significant differ-
 225 ences as to radiation or chemotherapy between the two groups were observed.

226 **Table 3.** Characterization of antineoplastic therapy.


	Total cohort (n=300)		CTRL (n=222)		COMB (n=78)		p-value
	N	%	N	%	N	%	
Radiation, bone	25	8.3	17	7.7	8	10.3	0.64
Radiation, brain	26	8.7	17	7.7	9	11.5	0.42
Radiation, primary tumour	33	11.0	21	9.5	12	15.4	0.22
Radiation, abdomen	1	0.3	1	0.5	0	0	1
Surgery	33	11.0	19	8.6	14	17.9	0.03
Chemotherapy	12	4.0	12	5.4	0	0	0.08
First-line immunotherapy	173	57.7	136	61.3	37	47.7	0.05
PD-L1/PD-1/CTL-A4 inhibitors							0.48
PD-L1 inhibitors	22	7.3	15	6.8	7	9.0	
PD-1 inhibitors	275	91.7	204	91.9	71	91.0	
CTL-A4 inhibitor	3	1.0	3	1.4	0	0	

227 Oncological therapy; n, number of patients; %, percent. CTL-A4, cytotoxic T-lymphocyte antigen 4;
 228 PD-L1, programmed death ligand; PD-1, programmed cell death protein 1; CRTL, patients receiv-
 229 ing PD-1/PD-L1 inhibitors without VA therapy; COMB, patients receiving PD-1/PD-L1 inhibitors
 230 plus VA therapy

231 **3.4. Characterization of Combinational PD-1/PD-L1 Inhibitor and VA Therapy**

232 The median duration of PD-1/PD-L1 therapy was 135 days (IQR 48-242 days) or 4.42
 233 months (IQR 1.6-7.9 months) while VA therapy lasted in median 242 days (IQR 48-464
 234 days) or 7,9 months (IQR 1,6-15,2 months).

235 Among the patients who received PD-1 inhibitors (either pembrolizuamb or
 236 nivolumab) 50.7% received concomitant intravenous, 36% concomitant subcutaneous,
 237 and 13.3% concomitant intratumoral abnobaViscum® therapy, see figure 2.



238 **Figure 2.** Characterization of combinational PD-1/PD-L1 inhibitor and abnobaViscum® therapy;
 239 Abnoba, abnobaViscum® therapy; iv, intravenous; sc, subcutaneous; it, intratumoral.
 240

241 Among the patients who received PD-L1 inhibitors (either atezolizumab or
 242 durvalumab) 25% received concomitant intravenous and 75% concomitant subcutaneous
 243 abnobaViscum® therapy, see figure 2. In most cases the intravenous, subcutaneous or
 244 intratumoral abnobaViscum® therapy was abnobaViscum® fraxini (fraxini = ash tree) VA
 245 extract being applied to the patients at different doses and different application forms,
 246 see table 4. From all patients 37.2% patients received intravenous abnobaViscum® fraxini
 247 with VA from other producers, see table 4. Combinations with VA from other producers
 248 were in cases of subcutaneous abnobaViscum® fraxini application 19.2% and in
 249 intratumoral application 7.7% of all cases, see table 4. Other abnobaViscum® applications
 250 included subcutaneous abnobaViscum® abietis (fir tree), amygdali (almond tree) or
 251 quercus (oak tree) extracts that were combined VA from other producers (4.2%).


252 **Table 4.** Application and combination forms of add-on abnobaViscum® therapy

	combination with other VA
	%
abnobaViscum® fraxini iv	37.2
abnobaViscum® fraxini sc	19.2
abnobaViscum® fraxini it	7.7
abnobaViscum®, other	4.2

253 Characterization of VA therapy; VA, Viscum album L.; NA, not applicable; n, number; %, percent;
 254 iv, intravenous; sc, subcutaneous; it, intratumoral; other, other host tree.

255 *3.5. Overall Survival of Advanced or Metastasized NSCLC Patients treated with PD-1/PD-L1*
 256 *Inhibitors Plus Add-on AbnobaViscum®*

257 A Kaplan-Meier survival analysis was performed for three hundred patients. Re-
 258 garding the three-year survival, the COMB treatment (PD-1/PD-L1 inhibitors + abno-
 259 baViscum® therapy) demonstrated a survival advantage compared to the CTRL group
 260 (PD-1/PD-L1 inhibitors without VA), as illustrated in figure 3. The median survival in the
 261 COMB group was 13.8 months (95%CI: 9.2 – 22 months), which is seven months longer
 262 than the median survival in the CTRL group which was 6.8 months (95%CI: 4.9 – 10.4
 263 months). The log-rank test showed a significant difference ($X^2 = 7.9, p=0.005$), as detailed
 264 in table 5. Out of the 300 patients, 187 patients (62.3%) died during the total observational
 265 period, with 62.8% (n = 49) in the COMB group and 62.2% (n = 138) in the CTRL group.
 266 The three-year survival rate was 16.5% in the COMB group, which is twice as high as the
 267 8% three-year survival rate in the CTRL group.



268
 269 **Figure 3.** Kaplan–Meier survival curves displaying three-year survival. according to treatment in
 270 advanced or metastasized NSCLC (n=300); Log-rank test: $X^2 = 7.9, p=0.005$; Ctrl, PD-1/PD-L1 in-
 271 hibitors; Comb, PD-1/PD-L1 inhibitors + abnobaViscum® therapy.

272 **Table 5.** Median overall survival in patients with advanced or metastasized NSCLC in relation to
 273 treatment.

	<i>N</i>	<i>Events</i>	<i>Median [months]</i>	<i>95% CI [months]</i>
NSCLC, CTRL	222	138	6.8	4.9 – 10.4
NSCLC, COMB	78	49	13.8	9.2 – 22.0
Log rank test $X^2=7.9, p=0.005$				

274 *3.6. Add-on AbnobaViscum® Therapy is Associated with Reduced Hazard of Death in PD-L1*
 275 *Positive (≥1%) NSCLC Patients Treated with First-Line PD-1 Inhibitors*

276 The adjusted multivariate Cox proportional hazard analysis on PD-L1 positive ($\geq 1\%$)
277 patients with advanced or metastasized NSCLC receiving first-line anti-PD-1 treatment
278 indicated a statistically significant 75% reduction in the hazard of death (adjusted hazard
279 ratio – aHR: 0.25, 95%CI: 0.11– 0.60, $p = 0.002$) when abnobaViscum[®] therapy was added,
280 as outlined in table 6. This effect was independent of gender, age, ECOG performance
281 status, tumor stage, surgery, radiation, or PD-L1 TPS.

282 **Table 6.** Factors associated with hazard of death.

	aHR	(95% CI)	p-Value
abnobaViscum [®] therapy vs. non-VA	0.25	0.11 - 0.60	0.002**
Age	1.00	0.98 - 1.04	0.551
Female gender vs. male gender	0.78	0.42 - 1.45	0.430
ECOG	1.31	1.05 - 1.64	0.017*
Surgery vs. no surgery	0.84	1.19 - 0.33	0.726
UICC stage IV vs. stage III	1.84	0.65 - 5.23	0.250
Brain radiation vs. no radiation	0.99	0.39 - 2.47	0.975
PD-L1 TPS ≥ 50	0.60	1.66 - 0.34	0.090

283 Multivariate cox proportional analysis of factors linked to hazard of death in patients with ad-
284 vanced or metastasized PD-L1 positive NSCLC receiving first-line PD-1/PD-L1 inhibitors, n=110,
285 number of events 59, 11 observations deleted due to missing data; aHR, adjusted hazard ratio of
286 death ; VA, abnobaViscum[®]; UICC, UICC, union international contre le cancer; PD-L1, pro-
287 grammed death-ligand 1; TPS, tumor proportion score, Score (logrank) test = 21.45 on 8 df,
288 $p=0.006^{\text{®}}$

289 4. Discussion

290 In this RWD study we assessed the effectiveness of PD-1/PD-L1 inhibitor therapy
291 when combined with abnobaViscum[®] therapy in cancer patients. Our results indicate that
292 patients with advanced or metastasized NSCLC who received PD-1/PD-L1 inhibitors in
293 combination with abnobaViscum[®] therapy experienced improved survival compared to
294 those patients receiving PD-1/PD-L1 inhibitors alone. Furthermore, patients with a PD-L1
295 positive ($\geq 1\%$) NSCLC tumor treated with first-line PD-1 inhibitors in combination with
296 abnobaViscum[®] therapy had a better survival compared to patients treated with PD-1
297 inhibitors without add-on abnobaViscum[®] therapy regardless of gender, age, tumor
298 stage, ECOG performance score, oncological treatment, or PD-L1 TPS.

299 Findings from recent real-world data studies revealed that the combination of im-
300 mune checkpoint blockade and VA therapy in advanced or metastasized NSCLC patients
301 was associated with improved overall survival (64) and showed no safety concerns for
302 VA (13, 14, 40,47). First prospective data results of PD-1/PD-L1 inhibitor in combination
303 with VA therapy (Phoenix-3 study) in advanced or metastatic NSCLC patients confirm
304 that the adverse event rates in patients receiving either PD-1/PD-L1 inhibitors alone or
305 PD-1/PD-L1 inhibitors with mistletoe did not significantly differ (47). Recently, a review
306 was published by the British Society for Integrative Oncology and Imperial College
307 London on integrative oncology therapies that support immune checkpoint inhibitor
308 therapy in solid tumours. The review concludes that the current data on immunotherapy
309 - mistletoe combinations are still limited, however they consistently show no safety signal
310 and are in accordance with clinical experiences of the authors (48). In accordance, the
311 national guideline for complementary therapies in oncological patients indicated that

312 there is no evidence of an increased rate of serious adverse events with the simultaneous
313 use of immune checkpoint inhibitors and VA (46).

314 Clinical evidence is increasingly demonstrating the survival benefits of VA in cancer
315 patients (35). Multiple systematic reviews, meta-analyses, and both clinical and real-
316 world data studies suggest a positive impact of VA extracts on survival outcomes
317 (10-12, 15-19, 65). The cause for the additive effect of VA on survival in NSCLC patients
318 treated with PD-1/PD-L1 inhibitors in this study remains open. At least, VA seem not to
319 interfere with the expression of PD-ligands on cancer cells in vitro (49). If they may interact
320 with the

321 PD-1 receptor on immunocompetent cells is not yet known. However, VA have been
322 shown to stimulate $\gamma\beta$ T cells (50), which have strong antitumor effects in several tumors
323 including NSCLC; these cells are also targeted by PD-1/PD-L1 inhibitors (51-53). This
324 could explain why VA enhance the effect of PD-1/PD-L1 inhibitor therapy. On the other
325 hand, blocking PD-L1 on cancer cells or PD-1 on T cells by specific antibodies may create
326 a microenvironment, which allows VA to exert their anticancer effect by other immunological
327 mechanisms. Thus, it has been indicated that various antigens found in VA extracts,
328 such as mistletoe lectin and viscotoxins, are potent modulators of several cell types
329 within both the innate and adaptive immune systems. These antigens interact with
330 toll-like receptors on antigen-presenting cells, as well as with macrophages, natural killer
331 cells, neutrophils, eosinophils, and T and B cells (54, 58). It is important to outline that VA
332 rather modulate and do not activate or inhibit immunocompetent cells, which explains
333 their good tolerability and the low incidence of severe side effects.

334 It has been shown that incidence of primary resistance to first- or second line
335 PD-1/PD-L1 inhibitors ranging from 21% to 44% in NSCLC patients could be lowered to
336 7% to 11% when this therapy was combined with chemotherapy (57). This effect may be
337 explained by the immunogenic cell death (ICD) induced by several chemotherapeutics
338 such as cyclophosphamide and oxaliplatin (58) making the tumor cells more visible to the
339 immune system so that primary resistance to PD-1/PD-L1 inhibitors can be overcome
340 (63). In relation to that, VA extracts enhance the maturation of dendritic cells (54), are
341 involved in the activation of immune cells (NK-cells, macrophages, dendritic cells (54, 58,
342 56), in cytokine (IL-1 β , IL-6, TNF-alpha) production (59, 60) as well as in antiangiogenic
343 (61) and pro-apoptotic processes (62) – altogether mechanisms that qualify VA for a role
344 in inducing ICD. During ICD the dying tumor cells release damage-associated molecular
345 patterns (DAMPs) activating dendritic cells which initiate and manage an effective immune
346 response against the tumor cells (63). Thus, add-on VA in the present study may be
347 involved in ICD and the overcoming of primary resistance to applied immune checkpoint
348 inhibitors in the present study resulting in longer overall survival in the NSCLC group
349 with the combined treatment. Last, but not least, improved survival in the COMB group
350 could be explained by a modified tumor microenvironment (TME). Immune checkpoint
351 inhibitors can reduce the immunosuppressive signals in the tumor microenvironment,
352 allowing immune cells to infiltrate and attack the tumor more effectively. VA extracts
353 have been shown to inhibit angiogenesis and thus change the TME for a reduced growth
354 of tumor cells and higher accessibility to immune cells.

355 *Limitations and Strength*

356 The non-randomized character of the present real-world data study limits our results.
357 However, the groups compared were well-balanced, minimizing the risk of comparing
358 heterogeneous patient populations in terms of tumor type, stage of the disease, or
359 oncological therapy. Additionally, potential biases were addressed using multivariable
360 logistic regression methods in the survival analyses to account for confounding factors. A
361 key strength of this real-world data study is that it reflects the actual use of PD-1/PD-L1
362 inhibitor therapy in NSCLC patients and is the first to demonstrate a positive association
363 between combined PD-1/PD-L1 inhibitor/abnobaViscum® therapy and improved survival.
364 Further research with larger and more diverse patient populations is needed to vali-

365 date these results and gain a deeper understanding of the effects of combined
366 PD-1/PD-L1 inhibitor and VA therapy in lung cancer treatment.

367 5. Conclusions

368 Our findings indicate that the addition of abnobaViscum[®] therapy is significantly
369 associated with enhanced survival in patients with advanced or metastatic NSCLC re-
370 ceiving standard PD-1/PD-L1 inhibitor therapy, regardless of age, gender, metastatic
371 status, or oncological treatment regimen. While these results highlight the clinical impact
372 of add-on VA therapy, they should be further complemented with analyses of RCT or
373 R-RCT.

374 Author contributions: FS and AT made significant contributions to the study design
375 and planning, collected, interpreted and analysed the data, drafted the manuscript,
376 critically revised it, and gave final approval for the version to be published. CG, RDH,
377 RK, SLO, HW and PG contributed substantially to data interpretation, critically revised
378 the manuscript, and gave final approval for the version to be published.

379 **Funding:** The Network Oncology is being funded through unrestricted research grants from
380 ABNOBA GmbH Niefern-Öschelbronn, Germany, and Helixor GmbH Rosenfeld, Germany. By
381 contract, researchers were independent from the funder.

382 **Institutional Review Board Statement:** The study was carried out in compliance with the Decla-
383 ration of Helsinki and received approval from the Ethics Committee of the Medical Association
384 Berlin (Ethik-Kommission der Ärztekammer Berlin, protocol code Eth-27/10).

385 **Informed Consent Statement:** Informed consent was obtained from all subjects in the study.

386 **Consent for publication:** All authors consented to this manuscript's publication.

387 **Data availability statement:** All relevant data are included in this manuscript.

388 **Acknowledgments:** We would like to express our gratitude to the colleagues from the hospital
389 Havelhöhe and the Research Institute Havelhöhe for their contributions to this work.

390 **Conflicts of Interest:** FS reports receiving grants from ABNOBA GmbH, Helixor Heilmittel GmbH,
391 and AstraZeneca GmbH, outside the submitted work. RDH reports a consulting or advisory role
392 with Amgen, Roche, Merck, Sanofi, Bayer, Ipsen, BMS, and MSD, as well as honoraria from Amgen,
393 AstraZeneca, Bayer, BMS, Boehringer, Ipsen, Lilly, Medac, Merck, MSD, Roche, Saladax, and
394 Sanofi, all outside the submitted work. RDH has also received research grants from Amgen, Medac,
395 Merck, Roche, Saladax, and Sanofi, outside the submitted work. PG reports travel expenses from
396 Ipsen Pharma and research grants from Helixor Heilmittel GmbH, outside the submitted work.
397 HW reports honoraria from AstraZeneca and Berlin-Chemie, outside the submitted work. CG re-
398 ports honoraria from AstraZeneca, Novartis, Chiesi, the German Society of Pneumology, Takeda,
399 the German S3-Guideline on Complementary Medicine in the Treatment of Oncological Patients,
400 and the Brandenburgian Cancer Society, all outside the submitted work. CG has also received
401 grants from Wala AG and Iscador AG, outside the submitted work. CG is a member of the Euro-
402 pean Respiratory Society, the German Society of Pneumology, Health Care Without Harm, the
403 German Alliance for Climate Change and Health, and the Society of Anthroposophic Physicians.
404 The remaining authors declare no competing interests.

405 References

- 406 1. Cancer.net, statistics, non-small cell lung cancer. Accessed 20.07.2023.
407 <https://www.cancer.net/cancer-types/lung-cancer-non-small-cell/statistics>
- 408 2. Langer CJ. Emerging immunotherapies in the treatment of non-small cell lung cancer (NSCLC): the role of immune checkpoint
409 inhibitors. *Am J Clin Oncol*. 2015 Aug;38(4):422-30. doi: 10.1097/COC.000000000000059. PMID: 24685885.
- 410 3. Waldman, A.D., Fritz, J.M. & Lenardo, M.J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. *Nat*
411 *Rev Immunol* **20**, 651–668 (2020). <https://doi.org/10.1038/s41577-020-0306-5>
- 412 4. EMA. EPAR Keytruda. <https://www.ema.europa.eu/en/medicines/human/EPAR/keytruda>
- 413 5. Bristol-Myers_Squibb. Positive Opinion Recommendation EMA. Accessed 21.07.2023
414 [https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommendation-Approval-](https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommendation-Approval-of-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Combined-with-Two-Cycles-of-Chemotherapy-as-First-Line-Treatment-of-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx)
415 [of-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Combined-with-Two-Cycles-of-Chemotherapy-as-First-Line-Treatment-of-Me-](https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommendation-Approval-of-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Combined-with-Two-Cycles-of-Chemotherapy-as-First-Line-Treatment-of-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx)
416 [tastatic-Non-Small-Cell-Lung-Cancer/default.aspx](https://news.bms.com/news/details/2020/Bristol-Myers-Squibb-Receives-Positive-CHMP-Opinion-Recommendation-Approval-of-Opdivo-nivolumab-Plus-Yervoy-ipilimumab-Combined-with-Two-Cycles-of-Chemotherapy-as-First-Line-Treatment-of-Metastatic-Non-Small-Cell-Lung-Cancer/default.aspx)
- 417 6. EMA. EPAR Opdivo. Accessed 20.07.2023. <https://www.ema.europa.eu/en/medicines/human/EPAR/opdivo>

- 418 7. EMA. EPAR Imfinzi. Accessed 21.07.2023. <https://www.ema.europa.eu/en/medicines/human/EPAR/imfinzi>
- 419 8. EMA. EPAR Libtayo. Accessed 21.07.2023. <https://www.ema.europa.eu/en/medicines/human/EPAR/libtayo>
- 420 9. EMA. EPAR Tecentriq. Accessed 21.07.2023. <https://www.ema.europa.eu/en/medicines/human/EPAR/tecentriq>
- 421 10. Schad F, Thronicke A, Steele ML, Merkle A, Matthes B, Grah C, Matthes H. Overall survival of stage IV non-small cell lung
422 cancer patients treated with *Viscum album* L. in addition to chemotherapy, a real-world observational multicenter analysis.
423 PLoS One. 2018 Aug 27;13(8):e0203058. doi: 10.1371/journal.pone.0203058. Erratum in: PLoS One. 2022 Aug 16;17(8):e0273387.
424 PMID: 30148853; PMCID: PMC6110500.
- 425 11. Bar-Sela G, Wollner M, Hammer L, Agbarya A, Dudnik E, Haim N. Mistletoe as complementary treatment in patients with
426 advanced non-small-cell lung cancer treated with carboplatin-based combinations: a randomised phase II study. Eur J Cancer.
427 2013;49:1058-1064
- 428 12. Salzer G, Danmayr E, Wutzholfer F, et al.: [Adjuvant Iscador® treatment of non-small cell bronchial carcinoma. Results of a
429 randomized study]. Dtsch Z Onkol 23 (4): 93-8, 1991.
- 430 13. Thronicke A, Steele ML, Grah C, Matthes B, Schad F. Clinical safety of combined therapy of immune checkpoint inhibitors and
431 *Viscum album* L. therapy in patients with advanced or metastatic cancer. BMC Complement Altern Med. 2017 Dec 13;17(1):534
- 432 14. Thronicke A, Oei SL, Grah C, Matthes B, Schad F. Nivolumab-induced toxicity profile in patients with advanced or metasta-
433 sized lung cancer treated with *Viscum album* L. extracts. Abstract. German Cancer Congress, 2018
- 434 15. Loef M, Walach H. Survival of Cancer Patients Treated with Non-Fermented Mistletoe Extract: A Systematic Review and
435 Meta-Analysis. Integr Cancer Ther. 2022 Jan-Dec;21:15347354221133561. doi: 10.1177/15347354221133561. PMID: 36324298;
436 PMCID: PMC9634211.
- 437 16. Loef M, Walach H. Survival of Cancer Patients Treated with Non-Fermented Mistletoe Extract: A Systematic Review and Me-
438 ta-Analysis. Integr Cancer Ther. 2022 Jan-Dec;21:15347354221133561. doi: 10.1177/15347354221133561. PMID: 36324298;
439 PMCID: PMC9634211.
- 440 17. Tröger W, Galun D, Reif M, Schumann A, Stanković N, Milićević M. *Viscum album* [L.] extract therapy in patients with locally
441 advanced or metastatic pancreatic cancer: a randomised clinical trial on overall survival. Eur J Cancer. 2013 Dec;49(18):3788-97.
442 doi: 10.1016/j.ejca.2013.06.043. Epub 2013 Jul 24. PMID: 23890767.
- 443 18. Axtner J, Steele M, Kröz M, Spahn G, Matthes H, Schad F. Health services research of integrative oncology in palliative care of
444 patients with advanced pancreatic cancer. BMC Cancer. 2016;16:579. Published 2016 Aug 2. doi:10.1186/s12885-016-2594-5
- 445 19. Loef M, Walach H. Quality of life in cancer patients treated with mistletoe: a systematic review and meta-analysis. BMC
446 Complement Med Ther. 2020 Jul 20;20(1):227. doi: 10.1186/s12906-020-03013-3. PMID: 32690087; PMCID: PMC7370416.
- 447 20. Pelzer F, Loef M, Martin DD, Baumgartner S. Cancer-related fatigue in patients treated with mistletoe extracts: a systematic
448 review and meta-analysis. Support Care Cancer. 2022 Aug;30(8):6405-6418. doi: 10.1007/s00520-022-06921-x. Epub 2022 Mar 3.
449 PMID: 35239008; PMCID: PMC9213316.
- 450 21. Kienle GS, Kiene H. Review article: Influence of *Viscum album* L (European mistletoe) extracts on quality of life in cancer
451 patients: a systematic review of controlled clinical studies. Integr Cancer Ther. 2010 Jun;9(2):142-57. doi:
452 10.1177/1534735410369673. Epub 2010 May 18. PMID: 20483874.
- 453 22. Piao BK, Wang YX, Xie GR, Mannmann U, Matthes H, Beuth J, Lin HS. Impact of complementary mistletoe extract treatment on
454 quality of life in breast, ovarian and non-small cell lung cancer patients. A prospective randomized controlled clinical trial.
455 Anticancer Research, 2004;24:303-310
- 456 23. Tröger W, Zdrale Z, Tisma N, Matijasevic M. Additional therapy with a mistletoe product during adjuvant chemotherapy of
457 breast cancer patients improves quality of life: an open randomized clinical pilot trial. ECAM, 2014;2014:01
- 458 24. Thies A, Dautel P, Meyer A, Pfüller U, Schumacher U. Low-dose mistletoe lectin-I reduces melanoma growth and spread in a
459 scid mouse xenograft model. Br J Cancer. 2008 Jan 15;98(1):106-12. doi: 10.1038/sj.bjc.6604106. Epub 2007 Nov 20. PMID:
460 18026191; PMCID: PMC2359693.
- 461 25. Büssing A, Suzart K, Bergmann J, Pfüller U, Schietzel M, Schweizer K. Induction of apoptosis in human lymphocytes treated
462 with *Viscum album* L. is mediated by the mistletoe lectins. Cancer Lett. 1996 Jan 19;99(1):59-72. doi:
463 10.1016/0304-3835(95)04038-2. PMID: 8564930.
- 464 26. Elluru S, Duong Van Huyen JP, Delignat S, Prost F, Bayry J, Kazatchkine MD, Kaveri SV. Molecular mechanisms underlying the
465 immunomodulatory effects of mistletoe (*Viscum album* L.) extracts Iscador. Arzneimittelforschung. 2006 Jun;56(6A):461-6. doi:
466 10.1055/s-0031-1296813. PMID: 16927527.
- 467 27. Samtleben R, Hajto T, Hostanska K, et al.: Mistletoe lectins as immunostimulants (chemistry, pharmacology and clinic). In:
468 Wagner H, ed.: Immunomodulatory Agents from Plants. Birkhauser Verlag, 1999, pp 223-41.
- 469 28. Hajto T, Hostanska K, Frei K, Rordorf C, Gabius HJ. Increased secretion of tumor necrosis factors alpha, interleukin 1, and
470 interleukin 6 by human mononuclear cells exposed to beta-galactoside-specific lectin from clinically applied mistletoe extract.
471 Cancer Res. 1990 Jun 1;50(11):3322-6. PMID: 2334925.
- 472 29. Büssing A. Immune modulation using mistletoe (*Viscum album* L.) extracts Iscador. Arzneimittelforschung. 2006;56:508-515
- 473 30. Tröger W, Jezdić S, Ždrale Z, et al.: Quality of life and neutropenia in patients with early stage breast cancer: a randomized pilot
474 study comparing additional treatment with mistletoe extract to chemotherapy alone . Breast Cancer: Basic and Clinical Re-
475 search 3: 35-45, 2009.
- 476 31. Schad F, Axtner J, Happe A, Breitkreuz T, Paxino C, Gutsch J, Matthes B, Debus M, Kröz M, Spahn G, Riess H, von Laue HB,
477 Matthes H. Network Oncology (NO) – a clinical cancer registry for health services research and the evaluation of integrative
478 therapeutic interventions in anthroposophic medicine. Forsch Komplementmed. 2013;20(5):353-60. Doi: 10.1159/000356204.
479 PMID: 24200825.

- 480 32. AbnobaVISCUM®. Summary of product characteristics. Accessed 21.07.2023.
481 https://www.abnoba.de/wp-content/uploads/2022/03/SmPC-all-products_2021_EN-unofficial.pdf
- 482 33. Fan Y, Xie W, Huang H, Wang Y, Li G, Geng Y, Hao Y, Zhang Z. Association of Immune Related Adverse Events With Efficacy
483 of Immune Checkpoint Inhibitors and Overall Survival in Cancers: A Systemic Review and Meta-analysis. *Front Oncol.* 2021
484 Apr 12;11:633032. doi: 10.3389/fonc.2021.633032. PMID: 33912454; PMCID: PMC8072154.
- 485 34. Schoenfeld DA. Sample-size formula for the proportional-hazards regression model. *Biometrics.* 1983 Jun;39(2):499-503. PMID:
486 6354290.
- 487 35. R Core Team (2021). R: A language and environment for statistical computing. R Foundation for Statistical Computing, Vienna,
488 Austria. URL <https://www.R-project.org/>.
- 489 36. Thomas A. Gerds (2019). prodlim: Product-Limit Estimation for Censored Event History Analysis. R package, version
490 2019.11.13. <https://CRAN.R-project.org/package=prodlim>
- 491 37. Alboukadel Kassambara, Marcin Kosinski and Przemyslaw Biecek (2021). survminer: Drawing Survival Curves using
492 'ggplot2'. R package version 0.4.9. <https://CRAN.R-project.org/package=survminer>
- 493 38. Schad F, Steinmann D, Oei SL, Thronicke A, Grah C. Evaluation of quality of life in lung cancer patients receiving radiation and
494 Viscum album L.: a real-world data study. *Radiat Oncol.* 2023 Mar 6;18(1):47. doi: 10.1186/s13014-023-02234-3. PMID: 36879290;
495 PMCID: PMC9990362
- 496 39. Schad F, Axtner J, Kroz M, Matthes H, Steele ML. Safety of Combined Treatment With Monoclonal Antibodies and Viscum
497 album L Preparations. *Integr Cancer Ther.* 2018;17:41-51
- 498 40. Schad F, Thronicke A. Safety of Combined Targeted and Helixor®*Viscum album* L. Therapy in Breast and Gynecological Cancer
499 Patients, a Real-World Data Study. *Int J Environ Res Public Health.* 2023 Jan 31;20(3):2565. doi: 10.3390/ijerph20032565. PMID:
500 36767928; PMCID: PMC9916034.
- 501 41. Thronicke A, Oei SL, Merkle A, Matthes H, Schad F. Clinical Safety of Combined Targeted and *Viscum album* L. Therapy in
502 Oncological Patients. *Medicines (Basel).* 2018 Sep 6;5(3):100. doi: 10.3390/medicines5030100. PMID: 30200590; PMCID:
503 PMC6164814.
- 504 42. Lin PY, Sun L, Thibodeaux SR, Ludwig SM, Vadlamudi RK, Hurez VJ, et al. B7-H1-dependent sex-related differences in tumor
505 immunity and immunotherapy responses. *J Immunol* (2010) 185:2747–53. doi: 10.4049/jimmunol.1000496
- 506 43. Ye Y, Jing Y, Li L, Mills GB, Diao L, Liu H, Han L. Sex-associated molecular differences for cancer immunotherapy. *Nat*
507 *Commun.* 2020 Apr 14;11(1):1779. doi: 10.1038/s41467-020-15679-x. PMID: 32286310; PMCID: PMC7156379.
- 508 44. Madala S, Rasul R, Singla K, Sison CP, Seetharamu N, Castellanos MR. Gender Differences and Their Effects on Survival Out-
509 comes in Lung Cancer Patients Treated With PD-1/PD-L1 Checkpoint Inhibitors: A Systematic Review and Meta-Analysis. *Clin*
510 *Oncol (R Coll Radiol).* 2022 Dec;34(12):799-809. doi: 10.1016/j.clon.2022.03.010. Epub 2022 Apr 7. PMID: 35400597.
- 511 45. Gu Y, Tang YY, Wan JX, Zou JY, Lu CG, Zhu HS, Sheng SY, Wang YF, Liu HC, Yang J, Hong H. Sex difference in the expression
512 of PD-1 of non-small cell lung cancer. *Front Immunol.* 2022 Oct 20;13:1026214. doi: 10.3389/fimmu.2022.1026214. PMID:
513 36341395; PMCID: PMC9632486.
- 514 46. Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft, Deutsche Krebshilfe, AWMF): Komplementärmedizin in der
515 Behandlung von onkologischen PatientInnen, Langversion 1.1, 2021, AWMF Registernummer: 032/055OL,
516 <https://www.leitlinienprogramm-onkologie.de/leitlinien/komplementaermedizin/>
- 517 47. Oei SL, Kunc K, Reif M, Weissenstein U, Weiß T, Wüstefeld H, Matthes H, Grah C. Prospective observational stud of advanced
518 or metastatic NSCLC patients treated with *Viscum album* L. extracts in combination with PD-1/PD-L1 blockade (PHOENIX-III).
519 *Oncol Res Treat, DO* 10.1159/000496362, vol. 42, suppl. 2, <https://doi.org/10.1159/000496362>.
- 520 48. Fuller-Shavel, N, Krell, J. Integrative Oncology Approaches to Supporting Immune Checkpoint Inhibitor Treatment of Solid
521 Tumours. *Curr Oncol Rep* (2024). <https://doi.org/10.1007/s11912-023-01492-4>
- 522 49. Devi S, Grundemann C, Huber R, Kowarschik S. Characterization of *Viscum album* L. Effect on Immune Escape Proteins
523 PD-L1, PD-L2, and MHC-I in the Prostate, Colon, Lung, and Breast Cancer Cells. *Complement Med Res.* 2023;30(5):386-392
- 524 50. Ma L, Phalke S, Stevigny C, Souard F, Vermijlen D. Mistletoe-Extract Drugs Stimulate Anti-Cancer Vgamma9Vdelta2 T Cells.
525 *Cells.* 2020;9(6)
- 526 51. de Vries NL, van de Haar J, Veninga V, et al. gammadelta T cells are effectors of immunotherapy in cancers with HLA class I
527 defects. *Nature.* 2023;613(7945):743-750
- 528 52. Gemes N, Balog JA, Neuperger P, et al. Single-cell immunophenotyping revealed the association of CD4+ central and CD4+
529 effector memory T cells linking exacerbating chronic obstructive pulmonary disease and NSCLC. *Front Immunol.*
530 2023;14:1297577
- 531 53. Nada MH, Wang H, Hussein AJ, Tanaka Y, Morita CT. PD-1 checkpoint blockade enhances adoptive immunotherapy by hu-
532 man Vgamma2Vdelta2 T cells against human prostate cancer. *Oncimmunology.* 2021;10(1):1989789
- 533 54. Huber R, Classen K, Werner M and Klein R. In vitro immunoreactivity towards lectin-rich or viscotoxin-rich mistletoe (*Viscum*
534 *album* L.) extracts Iscador applied to healthy individuals. *Arzneimittelforschung,* 2006;56:447-456
- 535 55. Saha C, Das M, Stephen-Victor E, Friboulet A, Bayry J and Kaveri S V. Differential Effects of *Viscum album* Preparations on the
536 Maturation and Activation of Human Dendritic Cells and CD4(+) T Cell Responses. *Molecules,* 2016;21. DOI:
537 10.3390/molecules21070912
- 538 56. Zhou S, Yang H. Immunotherapy resistance in non-small-cell lung cancer: From mechanism to clinical strategies. *Front*
539 *Immunol.* 2023 Apr 6;14:1129465. doi: 10.3389/fimmu.2023.1129465. PMID: 37090727; PMCID: PMC10115980.
- 540 57. Wang YJ, Fletcher R, Yu J, Zhang L. Immunogenic effects of chemotherapy-induced tumor cell death. *Genes Dis.* 2018 May
541 17;5(3):194-203. doi: 10.1016/j.gendis.2018.05.003. PMID: 30320184; PMCID: PMC6176216.

- 542 58. Tabiasco J, Pont F, Fournie J J and Vercellone A. Mistletoe viscotoxins increase natural killer cell-mediated cytotoxicity. Eur J
543 Biochem, 2002;269:2591-2600.
- 544 59. Fischer A. Charakterisierung der immunmodulatorischen Wirkung von Mistelpräparaten auf Zellen des Immunsystems bei
545 Rindern. Dissertation: Universität Hannover; 2006
- 546 60. Büssing A. *Viscum album* L. – Mechanismen der Zytotoxizität. In: Scheer R, Bauer R, Becker H, Berg AP, Fintelmann V, editors.
547 Die Mistel in der Tumortherapie. Essen: KCV Verlag; 2001. p. 121-134.
- 548 61. Kienle G S and Kiene H. Die Mistel in der Onkologie: Fakten und konzeptionelle Grundlagen. Schattauer Verlag; Stuttgart,
549 Germany, 2003
- 550 62. Park YR, Jee W, Park SM, Kim SW, Bae H, Jung JH, Kim H, Kim S, Chung JS, Jang HJ. *Viscum album* Induces Apoptosis by
551 Regulating STAT3 Signaling Pathway in Breast Cancer Cells. Int J Mol Sci. 2023 Jul 26;24(15):11988. doi: 10.3390/ijms241511988.
552 PMID: 37569363; PMCID: PMC10418465.
- 553 63. Krysko, D., Garg, A., Kaczmarek, A. et al. Immunogenic cell death and DAMPs in cancer therapy. Nat Rev Cancer 12, 860–875
554 (2012). <https://doi.org/10.1038/nrc3380>
- 555 64. Schad F, Thronicke A, Hofheinz R-D, Matthes H, Grah C. Patients with Advanced or Metastasised Non-Small-Cell Lung Can-
556 cer with *Viscum album* L. Therapy in Addition to PD-1/PD-L1 Blockade: A Real-World Data Study. *Cancers*. 2024; 16(8):1609.
557 <https://doi.org/10.3390/cancers16081609>
- 558 65. Hofinger J, Kaesmann L, Buentzel J, Scharpenberg M, Huebner J. Systematic assessment of the influence of quality of studies
559 on mistletoe in cancer care on the results of a meta-analysis on overall survival. J Cancer Res Clin Oncol. 2024 Apr
560 29;150(4):219. doi: 10.1007/s00432-024-05742-1. PMID: 38679615; PMCID: PMC11056339.